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The concept that type 2 diabetesmellitus (T2DM) can be reversedwith an intestinal operation is coun-
terintuitive. How could our costliest dis-
ease be forced into full, durable, and safe
remission with the bypass of a few inches
of intestine?
Counterintuitive or not, it’s true. Ac-
cordingly, we take notice when Sjöström
and colleagues (1) in the Swedish Obese
Subjects (SOS) study, the longest and
most complete bariatric surgery outcome
study in the world, document in this issue
that bariatric surgery reduces the inci-
dence of heart attacks. The SOS is a
prospective, nonrandomized, controlled
interventional trial on the effect of bariatric
surgery on mortality and morbidity com-
pared with conventional treatment that
enrolled 4,047 obese individuals from 1
September 1987 to 31 January 2001. Of
these, 2,010 underwent bariatric surgery,
and a contemporary matched group of
2,037 did not. The current report com-
pared the 345 diabetic patients who un-
derwent bariatric surgery with the 262
who did not. The authors found that “bari-
atric surgery was associated with a re-
duced myocardial infarction incidence”
(38/345 [11.0%] in the surgery vs. control
group 43/262 [16.4%] [P = 0.017]). The
effect was stronger in individuals with
higher serum cholesterol and triglycerides
at baseline. Not surprising, since the bari-
atric surgery was associated with signif-
icant decreases in body weight, blood
glucose, serum triglycerides, systolic and
diastolic blood pressure, and an increase
in HDL-cholesterol.
Others have reported similar beneﬁts
of bariatric surgery on cardiovascular
disease and mortality. Johnson et al. (2)
mined the data in the South Carolina
UB92 Inpatient Hospitalization Database
and Death Records and concluded that
in a cohort study of 349 bariatric surgical
patients and 903 control subjects that
“adjusting for age, comorbidities, and
event history, the relative risk of mortality
was reduced by 40 per cent in bariatric
patients compared with controls.” Sim-
ilarly, Batsis et al. (3), calculated the
Framingham and the Prospective Cardio-
vascular Munster cardiovascular risk
scores in 197 patients who underwent the
Roux-en-Y gastric bypass (RYGB) versus a
matched cohort of 163 individuals who
did not. With both scoring methods, car-
diovascular relative risk was reduced
from 79 to 18% with the Framingham in-
strument and from 62 to 8% to with the
Prospective Cardiovascular Munster
scores. In our study (4) of 232 severely
obese diabetic patients of whom 154 un-
derwent bariatric surgery versus 78 indi-
viduals who were also scheduled for but
did not undergo the operations mainly
because of failure to obtain insurance cov-
erage, the mortality was 78% less in the
operated group. This report from the
SOS, in addition to their previous reports,
as well as the extensive publications of
other clinical series throughout the
world, should now be ample documenta-
tion that bariatric surgery is effective, ef-
ﬁcient, and safe.
Unfortunately, the relevance of the
SOS series is increasingly limited because
the operations used in the study no longer
reﬂect the practices of today. The vertical
banded gastroplasty performed in 227 of
the 345 (65.8%) patients is no longer
done. Their version of the vertical band-
ing performed in 61 (17.7%) patients was
not adjustable, and the 57 gastric by-
passes (RYGB) (16.5%) had alimentary
limbs that were shorter (60 cm) than
those used currently (100–150 cm). To-
day’s four accepted operations, the ad-
justable gastric band, the gastric sleeve,
the RYGB, and the biliopancreatic bypass
with a duodenal switch are far more effec-
tive in controlling type 2 diabetes than
these older procedures. For example,
our recent meta-analysis (5) involving
621 studies published in the English lan-
guage involving 135,246 patients found
diabetes remission rates of 56.7% for the
vertical banded gastroplasty and 95.1%
for the biliopancreatic bypass with duo-
denal switch. In short, the reduction in
myocardial infarctions in the SOS series
was achieved with operations that were
less effective in the treatment of T2DM
than those used today. For clariﬁcation
of this surgical jargon, Fig. 1 provides an
overview of these operations.
The second problem with the SOS
study is that the operations and the
perioperative care were not standardized
in the participating 25 surgical depart-
ments—frankly, a concern that has still
not been addressed in the most bariatric
surgical series published today. We may
refer to the “gastric bypass operation” as a
single deﬁned procedure, but these oper-
ations actually differ signiﬁcantly across
the U.S. in terms of the surgical ap-
proaches: 1) open versus laparoscopic; 2)
sizes of the gastric pouches; 3) direction of
the pouches, i.e., horizontal versus vertical;
4) the diameters of the gastroenterostomy;
5) construction of the gastroenterostomy,
i.e., stapled versus hand sewn; 6) routing of
the jejunal loops (antecolic vs. retrocolic);
7) length of the biliopancreatic limb; 8)
length of the alimentary limbs; 9) sizes
of the jejuno-jejunostomy; 10) use of
drains; and 11) use of limiting gastric
bands—if you do the math, it turns out
there are over 1,000 variations. In addi-
tion, and of special relevance tometabolic
studies, protocols generally do not stan-
dardize perioperative care, including
speciﬁcation of anesthetic agents, anti-
biotics, and other drugs. We really need
to address this serious issue in the design
of future studies.
Another ﬁnding in the SOS study that
deserves comment is that “baseline fasting
insulin levels rather than BMI predicted
the surgery treatment beneﬁt on cardio-
vascular event.” The failure of the BMI
(kg/m2) as a predictive tool is not surpris-
ing. The BMI, a simple measure of height
over weight that is easily captured in a
clinical visit, may be a useful tool for ep-
idemiologic studies, but it is not at all a
reliable measure of adiposity. It fails to
allow for differences in sex, race, age, ﬁt-
ness, and fat distribution (6). This is a
serious issue because access to bariatric
surgery is denied by insurance carriers
unless the patient’s BMI is $40 or $35
in those with serious comorbidities. This
faulty measure discriminates primarily
against those who need it most: the poor,
females, Asians, and African Americans.
The continued use of the BMI as a cruel
gate to deny patients access to the surgery
is ever harder to explain.
Their ﬁnding that fasting insulin
levels can predict outcomes is also of
interest. This ﬁts with the observations
that 1) basal levels of insulin increase with
the progression of T2DM and 2) gastric
bypass produces simultaneous correction
of hyperglycemia and hyperinsulinemia
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(also counterintuitive) in a matter of days
(7,8). It would be a major boon if this
simple test proved to be a reliable predic-
tor of bariatric outcomes.
Our Swedish colleagues have made
major contributions to our understanding
of bariatric surgery. However, we need to
move on. The evidence, counterintuitive
or not, is in. Durable and full remission of
T2DM is now achieved daily in the U.S.
in over 450 certiﬁed Centers of Excel-
lence. The task now is to use the oppor-
tunities offered by bariatric surgery to
explore the mechanisms that produce
T2DM. We have some tantalizing clues
from recent studies of the microbiome,
gut signaling in response to food, incretin
function, insulin action, mitochondrial
responses, and control of energy metab-
olism. The more rapidly we pursue these
questions, the greater our chances for
ﬁnding medications that can rival the
surgical results.
So why is S.O.S.—a tragic, ageless
mnemonic that screams “save our
souls”—in the title of this commentary?
It is there to emphasize that less than 1%
of those who could beneﬁt from bariatric
surgery have access to this remarkably ef-
fective, life-saving treatment. Our pa-
tients deserve better. S.O.S!
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Figure 1—Diagrams of bariatric operations.
Shading indicates contact of food with the gut
wall. The top line indicates the three oper-
ations in the SOS study: gastric banding (GB),
vertical banded gastroplasty (VBG), and
RYGB. The lower line illustrates the four
commonly performed procedures today: ad-
justable gastric banding (AGB), RYGB, gastric
sleeve (GS), and biliopancreatic bypass with
duodenal switch (DS). The limb lengths are
schematic; current alimentary limb lengths are
100–150 cm in the RYGB, whereas the bil-
iopancreatic bypass with duodenal switch ex-
cludes most of the small bowel to a short
common channel 100 cm proximal to the
ileocecal junction.
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